Bedrijfsoverzicht
IceCure Medical Ltd is a commercial-stage medical device company dedicated to the research, development, and marketing of cryoablation systems, disposables, and technologies specifically designed for treating tumors. The enterprise operates within the Healthcare sector, focusing on the Medical Devices industry, which encompasses the creation and distribution of essential equipment for clinical procedures. The company's scale is defined by a market capitalization of $26.25M and an annual revenue of $3.38M, supported by a workforce of 67 employees. These financial metrics indicate that IceCure Medical Ltd functions as a small-cap entity with limited revenue generation relative to its market valuation, suggesting a company in a growth phase where market expectations are priced into the stock rather than current cash flows. The significant disparity between the market cap and the revenue figure highlights the speculative nature of the valuation, which often reflects potential future expansion in the United States, Japan, India, China, Israel, and international markets rather than established profitability.
Financiële gezondheid
The company reported a revenue of $3.38M over the trailing twelve months, while the net income stood at $-15,057,000 and EBITDA was recorded at $-14,799,000. The substantial negative gap between the positive revenue of $3.38M and the net loss of $-15,057,000 reveals a highly leveraged cost structure characterized by significant operating expenses that far exceed the income generated from sales. Free cash flow for the period was $-8,915,750, which indicates a lack of financial flexibility and suggests that the company is burning through cash reserves to fund its research and development activities. Profitability is further evidenced by a gross margin of 36.3%, which shows that the cost of goods sold is managed reasonably well, yet the operating margin is severely depressed at -329.6%, indicating that general and administrative costs are disproportionately high. The profit margin is listed at 0.0%, confirming that the company has not achieved net profitability on a per-dollar-of-sales basis during this period. On the balance sheet, the company holds $8.90M in cash against $217,000 in debt, resulting in a debt-to-equity ratio of 2.40. Despite the low absolute level of debt, the high debt-to-equity ratio implies a leveraged capital structure relative to the equity base, though the cash position provides a substantial buffer. The current ratio stands at 2.61, which indicates a strong short-term liquidity position where current assets are more than double current liabilities, ensuring the ability to meet obligations as they come due. Return on Equity is -188.8% and Return on Assets is -71.3%, metrics that reveal management has yet to generate positive returns on the capital invested, reflecting the early-stage nature of the business model.
Waarderingsbeoordeling
Valuation metrics for the stock show a P/E ratio (TTM) of N/A due to the lack of earnings, while the forward P/E is -4.04. The negative forward P/E implies that the market expects earnings to remain negative in the immediate future or anticipates a turnaround that has not yet materialized in the price-to-earnings calculation. The price-to-book ratio is 2.61, which indicates that the market values the company at a premium of 161% over its net book value, suggesting high expectations for future asset appreciation or intangible value. Alternative valuation metrics include a price-to-sales ratio of 7.77 and an EV/EBITDA of -1.01. The elevated price-to-sales ratio relative to the small revenue base suggests that investors are pricing in significant future growth potential despite the current lack of profitability. The 52-week high is $1.40 and the 52-week low is $0.28. Based on the provided data range, the stock price sits within a volatile band, though the exact current price is not specified, the range demonstrates a wide trading spread of $1.12. The beta value is 2.52, which means the stock exhibits high price volatility and is expected to move with significantly greater amplitude than the broader market. This high beta indicates that the share price will likely experience sharp increases during market rallies and steep declines during market downturns, reflecting the risk profile associated with small-cap biotech or medical device firms.
Growth & Income
The company experienced a revenue growth rate of 46.2% year-over-year, while earnings growth is N/A due to the lack of positive earnings in the trailing period. The absence of earnings growth data implies that the primary driver of shareholder value creation is currently top-line expansion rather than margin improvement or profit generation. As a non-dividend payer, the company does not distribute a dividend yield or a payout ratio to shareholders. Instead, the company reinvests all available earnings, or in this case, all available cash flow, back into research, development, and market expansion activities to fuel future growth. This strategy prioritizes capital allocation toward innovation and market penetration over immediate income generation for investors. The overall growth and income profile is characterized by robust top-line expansion coupled with a complete absence of dividend income, reflecting a high-risk, high-reward capital allocation strategy typical of commercial-stage medical device companies.